NEW YORK, August 5, 2026, 06:08 EDT – Shares of Bluejay Diagnostics NASDAQ:BJDX rose 47% in premarket trading, while warrant funding for the company continues to depend on certain conditions.
- Bluejay shares were last quoted at $1.4694 in delayed premarket trade, rising 46.9%. Pre-market volume totaled 2.18 million shares.
- The share price stayed 29.2% under the $2.075 Series G and H warrant strike price. Full cash exercise of those warrants could generate $15.2 million.
- Bluejay’s investor website displayed no press releases following July 21 and contained no SEC filings after July 22.
Shares of Bluejay Diagnostics, Inc. NASDAQ:BJDX jumped ahead of Wednesday’s market open. The stock had gained 6.1% to close at $1.00 on Tuesday.
Despite the rally, Bluejay’s crucial financing benchmark was not reached. Shares continued to trade significantly under the $2.075 cash-exercise level for June warrants.
This affects the company’s available capital. Exercising all cash options may bring in approximately $15.2 million in extra gross proceeds. Bluejay secured around $7.7 million in net proceeds at the close of the financing.
No new announced corporate developments accounted for Wednesday’s increase. Bluejay’s most recent official update related to its finished SYMON-II enrollment. According to current disclosures, the price action seems to be driven by trading.
Trade performance comparison
| Trading measure | Reading | Comparison |
|---|---|---|
| Tuesday’s closing price | $1.0000 | Rose 6.12% |
| Wednesday premarket price | $1.4694 | Gained 46.94% |
| Pre-market volume | 2.18 million | Equals 2.33 times the declared float |
| Public float | 936,430 shares | Lower than premarket trading volume |
| Short interest | 569,680 shares | 60.83% of float as of July 15 |
By 4:21 a.m. EDT, premarket trading volume was more than double the size of the public float. According to the most recent short-interest data, over 60% of the float was sold short. This setup has the potential to intensify both upward and downward price movements.
The gap from the warrant strike stood at 29.2%. From the current stock price, Bluejay required a further 41.2% rise to hit $2.075.
Comparing price and financing limits
| Reference point | Price or value | Distance from premarket price |
|---|---|---|
| Premarket indication | $1.4694 | Baseline |
| Series G/H exercise price | $2.0750 | Stock is 29.2% lower |
| Gain needed to reach strike | — | 41.2% increase required |
| June placement package price | $2.3250 | Stock is 36.8% lower |
| Potential warrant proceeds | $15.2 million | Dependent on complete cash exercise |
An increasing share price does not directly generate cash for the company. Warrant holders need to exercise their warrants and pay the strike price.
Bluejay stated that the June placement increased its projected runway through the first quarter of 2027. The company said an extended runway would depend on the full cash exercise of the warrants.
Runway and cash comparison
| Measure | Reported amount or timing |
|---|---|
| Cash as of March 31 | $3.684 million |
| Operating cash used in first quarter | $1.589 million |
| Net proceeds from June financing | About $7.7 million |
| Revised projected runway | First quarter of 2027 |
| Estimated additional capital needed through 2027 before financing | At least $20 million more |
The capital structure introduces an additional limitation. Bluejay has registered 11.22 million shares tied to warrants for potential resale, roughly 10.8 times greater than the 1.03 million shares listed as outstanding on June 17. Registration does not indicate that all underlying shares are issued or sold.
On July 21, Bluejay reached a key clinical milestone as it finished enrolling 750 participants for its SYMON-II sepsis trial. Early data indicated a mortality rate close to 17%.
Comparison of clinical datasets
| SYMON-II measure | Reading |
|---|---|
| Enrollment target | 750 patients |
| Patients enrolled | 750 |
| Preliminary 28-day mortality rate | Roughly 17% |
| Implied mortality events | Approximately 128 |
| Current stage | Ongoing data cleaning and statistical analysis |
| Earliest stated FDA submission timing | 2027 |
Initial calculation based on 750 patients and the 17% rate disclosed by the company. This figure does not represent the final reported outcome total.
Chief Executive Neil Dey called finishing enrollment earlier than planned “an important operational achievement” in the July update. Bluejay Diagnostics, Inc
Bluejay anticipates conducting data cleaning, analysis, and clinical reporting in the next several months. The Symphony platform is still considered investigational and does not have FDA clearance. The company earlier stated that a 510(k) submission is not planned before at least 2027.
Risks are still significant. The first-quarter report highlighted serious doubts about continued operations. Ongoing regulatory issues, persistent cash burn, and dilution from warrants could weigh on shareholders. With limited float and high short interest, the risk of a reversal is also elevated.
Investors are set to monitor if the premarket rise can persist through the regular session. Progress toward $2.075 would enhance warrant-exercise economics, though that would not ensure holders contribute the cash.
